TDM Not Yet Justified for Non-Anti-TNF IBD Therapies
This narrative review clarifies where exposure-response signals exist for newer biologics and small molecules in inflammatory bowel disease and, critically, why routine therapeutic drug monitoring cannot yet be recommended for any of them.
📅 Journal publication: 2026(online Aug 4, 2026)·Last updated: Aug 19, 2026
Could TDM unlock better outcomes for advanced IBD therapies?
Therapeutic drug monitoring (TDM) could enhance the efficacy of non-anti-tumor necrosis factor (TNF) therapies in inflammatory bowel disease (IBD). The review highlights limited but emerging evidence supporting TDM for non-anti-TNF therapies in IBD, potentially guiding dose adjustments. Current findings suggest TDM might improve treatment outcomes for advanced IBD therapies, though research is ongoing and evidence remains limited. TDM may improve non-anti-TNF therapy outcomes in IBD.
📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Free account, no credit card. Includes 1 full deep analysis every month.
Authors:Chater F, Butler TD, Limdi JK
Citation:Chater F, Butler TD, Limdi JK Therapeutic drug monitoring with non-anti-TNF advanced therapies in inflammatory bowel disease: current and evolving paradigms. Frontiers in gastroenterology (Lausanne, Switzerland). 2026;5:1860608. doi:10.3389/fgstr.2026.1860608